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Background:  The potential cost-effectiveness of RFA for AF, relative to antiarrhythmic drug (AAD) therapy, is important since decision making is 
also based on economic considerations. 
Methods:  The cost-effectiveness study was conducted from the third party payer’s perspective (Italian National Health Service, INHS), to compare 
RFA and ADT in patients with PAF. We collected and compared 1-year follow-up data from the 198 patients of the APAF study (JACC 2006) randomly 
assigned to catheter ablation (99 patients) or to new ADT (99 patients). Efficacy and direct medical costs were quantified. Sensitivity analyses were 
conducted to account for the uncertainties as well as to identify how estimates could vary under different assumptions for cardiovascular events 
(CV). Costs paid by the hospital to perform RFA were quantified and compared with the reimbursement provided by NHS. At the time of analyses 
(2009) 1 euro (€) corresponded to around 1.41 US (Dollars) $. 
Results:  In one year RFA cost was on average 6,923 €/patient while ADT was 6,773 €/patient. RFA cost driver was the cost of the procedure 
(82.9% of total costs), ADT cost driver was the cost of hospitalizations for cardiovascular reasons (48% of total costs). Using RFA generated an 
incremental cost-effectiveness ratio (ICER) of 239 €/patient AF-free, and an ICER=25 €/patient-month AF-free (149€/6.02 patient-months). 
Under different assumptions for CV event, RFA strategy appeared to be dominant (i.e. contemporarily more effective and less costly) in a best case 
hypothesis (up to 2000 €/patient saved in one year), or, in a worst case hypothesis, it could generate an ICER up to 800€/patient AF-free and 85 €/
patient-month AF-free. If the real costs are reimbursed to the hospital, the ICER increases to 7,000 €/patient AF-free, and to 736 €/patient-month 
free from AF gained.
Conclusion: RFA among patients with paroxysmal AF, who have already failed ADT treatment, is cost effective in just 1-year follow-up. However, 
currently RFA is much more costly to the provider hospital than the reimbursement received from INHS. If to perform RFA a reimbursement congruent 
with real costs is provided, the off-set of costs could be reached in a few years.
